Comments
Loading...

Verve Therapeutics Analyst Ratings

VERVNASDAQ
Logo brought to you by Benzinga Data
$6.16
At close: Jun 16 EDT
$6.17
0.010000.16%
Pre-Market: 5:12 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$62.00
Lowest Price Target1
$13.00
Consensus Price Target1
$31.13

Verve Therapeutics Analyst Ratings and Price Targets | NASDAQ:VERV | Benzinga

Verve Therapeutics Inc has a consensus price target of $31.13 based on the ratings of 10 analysts. The high is $62 issued by BMO Capital on July 18, 2022. The low is $13 issued by Goldman Sachs on December 15, 2022. The 3 most-recent analyst ratings were released by Guggenheim, Canaccord Genuity, and HC Wainwright & Co. on April 15, 2025, April 15, 2025, and April 14, 2025, respectively. With an average price target of $29.33 between Guggenheim, Canaccord Genuity, and HC Wainwright & Co., there's an implied 375.42% upside for Verve Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Feb
3
Mar
4
Apr
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Guggenheim
Canaccord Genuity
HC Wainwright & Co.
RBC Capital
Stifel

1calculated from analyst ratings

Analyst Ratings for Verve Therapeutics

Buy NowGet Alert
04/15/2025Buy Now—Cantor Fitzgerald
Rick Bienkowski28%
—UpgradeNeutral → OverweightGet Alert
04/15/2025Buy Now288.98%Guggenheim
Etzer Darout49%
$18 → $24MaintainsBuyGet Alert
04/15/2025Buy Now532.09%Canaccord Genuity
Whitney Ijem59%
$32 → $39MaintainsBuyGet Alert
04/14/2025Buy Now305.19%HC Wainwright & Co.
Mitchell Kapoor46%
$15 → $25MaintainsBuyGet Alert
03/25/2025Buy Now—Guggenheim
Seamus Fernandez63%
—ReiteratesBuy → BuyGet Alert
03/25/2025Buy Now143.11%HC Wainwright & Co.
Mitchell Kapoor46%
$15 → $15ReiteratesBuy → BuyGet Alert
03/04/2025Buy Now143.11%RBC Capital
Luca Issi46%
$17 → $15MaintainsOutperformGet Alert
02/28/2025Buy Now143.11%HC Wainwright & Co.
Mitchell Kapoor46%
$14 → $15MaintainsBuyGet Alert
11/06/2024Buy Now418.64%Canaccord Genuity
Whitney Ijem59%
$29 → $32MaintainsBuyGet Alert
11/06/2024Buy Now175.53%RBC Capital
Luca Issi46%
$20 → $17MaintainsOutperformGet Alert
11/06/2024Buy Now126.9%HC Wainwright & Co.
Mitchell Kapoor46%
$15 → $14MaintainsBuyGet Alert
08/12/2024Buy Now370.02%Canaccord Genuity
Whitney Ijem59%
$30 → $29MaintainsBuyGet Alert
08/12/2024Buy Now143.11%HC Wainwright & Co.
Mitchell Kapoor46%
$15 → $15ReiteratesBuy → BuyGet Alert
08/09/2024Buy Now224.15%RBC Capital
Luca Issi46%
$25 → $20MaintainsOutperformGet Alert
05/09/2024Buy Now143.11%HC Wainwright & Co.
Mitchell Kapoor46%
→ $15ReiteratesBuy → BuyGet Alert
04/03/2024Buy Now548.3%Stifel
Dae Gon Ha49%
$56 → $40MaintainsBuyGet Alert
02/28/2024Buy Now467.26%RBC Capital
Luca Issi46%
$35 → $35ReiteratesOutperform → OutperformGet Alert
09/13/2023Buy Now256.56%Cantor Fitzgerald
Rick Bienkowski28%
→ $22ReiteratesNeutral → NeutralGet Alert
08/29/2023Buy Now256.56%Cantor Fitzgerald
Rick Bienkowski28%
→ $22ReiteratesNeutral → NeutralGet Alert
08/15/2023Buy Now791.41%Guggenheim
Seamus Fernandez63%
$56 → $55MaintainsBuyGet Alert
08/11/2023Buy Now402.43%Credit Suisse
Richard Law48%
→ $31ReiteratesNeutral → NeutralGet Alert
06/16/2023Buy Now370.02%Canaccord Genuity
Whitney Ijem59%
→ $29ReiteratesBuy → BuyGet Alert
05/16/2023Buy Now467.26%RBC Capital
Luca Issi46%
→ $35ReiteratesOutperform → OutperformGet Alert
04/13/2023Buy Now370.02%Canaccord Genuity
Whitney Ijem59%
→ $29Initiates → BuyGet Alert
02/01/2023Buy Now240.36%Cantor Fitzgerald
Rick Bienkowski28%
→ $21Initiates → NeutralGet Alert
12/15/2022Buy Now110.7%Goldman Sachs
Andrea Tan40%
→ $13Initiates → SellGet Alert
11/08/2022Buy Now467.26%RBC Capital
Luca Issi46%
$42 → $35MaintainsOutperformGet Alert
10/06/2022Buy Now677.96%Credit Suisse
Richard Law48%
→ $48Initiates → NeutralGet Alert
08/25/2022Buy Now807.62%Stifel
Dae Gon Ha49%
$32 → $56UpgradeHold → BuyGet Alert
07/18/2022Buy Now904.86%BMO Capital
Kostas Biliouris35%
$48 → $62MaintainsOutperformGet Alert
06/17/2022Buy Now677.96%BMO Capital
Kostas Biliouris35%
→ $48Initiates → OutperformGet Alert

FAQ

Q

What is the target price for Verve Therapeutics (VERV) stock?

A

The latest price target for Verve Therapeutics (NASDAQ:VERV) was reported by Cantor Fitzgerald on April 15, 2025. The analyst firm set a price target for $0.00 expecting VERV to fall to within 12 months (a possible -100.00% downside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Verve Therapeutics (VERV)?

A

The latest analyst rating for Verve Therapeutics (NASDAQ:VERV) was provided by Cantor Fitzgerald, and Verve Therapeutics upgraded their overweight rating.

Q

When was the last upgrade for Verve Therapeutics (VERV)?

A

The last upgrade for Verve Therapeutics Inc happened on April 15, 2025 when Cantor Fitzgerald raised their price target to N/A. Cantor Fitzgerald previously had a neutral for Verve Therapeutics Inc.

Q

When was the last downgrade for Verve Therapeutics (VERV)?

A

There is no last downgrade for Verve Therapeutics.

Q

When is the next analyst rating going to be posted or updated for Verve Therapeutics (VERV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Verve Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Verve Therapeutics was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.

Q

Is the Analyst Rating Verve Therapeutics (VERV) correct?

A

While ratings are subjective and will change, the latest Verve Therapeutics (VERV) rating was a upgraded with a price target of $0.00 to $0.00. The current price Verve Therapeutics (VERV) is trading at is $6.17, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch